If selection criteria are to be based on family history of cancer for HR+/HER2-negative eBC patients in resource-constrained settings, GT for BRCA germline pathogenic variants can be limited to patients with known likely/pathogenic variants in high-penetrance BC susceptibility genes (including BRCA1/2) in at least one close blood relative with BC diagnosed at 50 years or less, epithelial ovarian nonmucinous cancer at any age, or high Gleason prostate cancer diagnosed at age less than 60 years. This evidence concerns the gene BRCA1 and Familial prostate cancer.